Surescripts, a leading health information exchange network, has acquired ActiveRADAR, a prominent health IT vendor specializing in identifying prescription alternatives. This collaboration aims to enhance patient care by providing comprehensive clinical and cost data at the point of prescribing. ActiveRADAR offers evidence-based therapeutic alternatives tailored to specific formularies, reducing costs for employers and employees by 15 to 20 percent. By prioritizing savings opportunities, ActiveRADAR’s analytical methods improve medication adherence and patient-provider engagement. The integration is set to optimize Surescripts’ data, ensuring faster access to insights and offering more options to healthcare providers.
Surescripts, a prominent health information exchange network, has recently acquired ActiveRADAR, a leading health IT vendor specializing in identifying alternative therapies for prescriptions. Surescripts’ network connects over two million healthcare professionals and providers, offering plan-level formulary data to facilitate informed patient discussions.
Frank Harvey, CEO of Surescripts, expressed the organization’s dedication to enhancing patient care, stating, “Our acquisition of ActiveRADAR reinforces our commitment to enriching our network solutions with comprehensive clinical and cost data at the point of prescribing.” The collaboration aims to simplify and expedite the process of initiating patients on the most suitable medications for their needs.
ActiveRADAR, previously known as RxTE Health, provides evidence-based therapeutic alternatives tailored to specific formularies and medical usage. The platform also offers corresponding dosage strengths, quantities, and plan-specific patient and health plan costs. By prioritizing savings opportunities and minimizing disruptions, ActiveRADAR’s analytical methods have significantly reduced costs for employers and employees, slashing expenses by 15 to 20 percent.
Dave Teckman, former CEO of ActiveRADAR, expressed enthusiasm about the agreement, emphasizing the positive impact on medication adherence and patient-provider engagement. ActiveRADAR’s extensive clinical catalog covers over 165 therapeutic categories, including 30 specialty drug categories and more than 33,000 drug pairs.
Lynne Nowak, MD, chief data & analytics officer of Surescripts, highlighted the significance of the collaboration, stating, “We are excited to welcome the ActiveRADAR team to Surescripts. Their vast therapeutic alternatives data will enable us to reduce drug expenses and offer more options when providing prescription pricing information to healthcare providers.” The integration of ActiveRADAR’s expertise is expected to enhance the value of Surescripts’ data and expedite access to valuable insights, ultimately improving patient experiences and streamlining the healthcare system.
